This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
APROM ID#: 2797; approval date: May 2011
Overview
Manage your diabetes
Insulin pens and needles
Social support
Overview
Disease areas
Overview
Growth hormone
Injection devices
Growth disorders
Exclusively for Health Care Professionals
Stay up to date on current diabetes themes, proved therapeutic options, and knowledge resources and tools for you and your patients & find detailed information on Novo Nordisk diabetes products: Tresiba® (insulin degludec), Victoza® (liraglutide injection), Levemir® (insulin detemir), NovoMix® (biphasic insulin aspart), NovoRapid® (insulin aspart), and our pens & devices.
Novo Nordisk provides localized information to HCPs in the following countries:
Why only for Health Care Professionals
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Overview
Haemostasis management
Product information
NovoSeven®
Dosing
Storage information
Vial information
Haemostasis
Management
Blood coagulation
Educational
Key papers
Treatment guidelines
Services & links
WFH patients' leaflet
Patient story
Disease areas
Congenital haemophilia
Acquired haemophilia
Factor VII deficiency
Glanzmann's thrombasthenia
Why only for Health Care Professionals
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Overview
Growth hormone therapy overview
Pharmaceutical information
Norditropin®
Indications
GHD (Growth hormone deficiency)
GHDA (Growth hormone deficiency) in adults
SGA (Small for gestational age)
Turner syndrome
Noonan syndrome
Skeletal dysplasia
Chronic renal disease
Prader-Willi syndrome
Injection devices
Norditropin® FlexPro®
Norditropin NordiFlex®
NordiPen® with Norditropin® SimpleXx®
Norditropin® NordiLet®
Needles
NovoFine®
Programmes & support
NordiNet® (outcomes registry)
NordiScience® (HCP support)
NordiCare® (Patient support)
Our partnership with Save the Children
Patient testimonials
Testimonials
Why only for Health Care Professionals
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Overview
Overview
Our products
Introduction
Activelle®
Eviana®
Novofem®
Estrofem®
Vagifem®
Convenience & compliance
Our history in HRT
About HRT
Introduction
Symptoms & complaints
Duration of treatment
Oestrogen
Progestogen
Continuous combined HRT
Sequential combined HRT
Low-dose HRT
Why only for Health Care Professionals
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Exclusively for Health Care Professionals
Stay up to date on current diabetes themes, proved therapeutic options, and knowledge resources and tools for you and your patients & find detailed information on Novo Nordisk diabetes products: Tresiba® (insulin degludec), Victoza® (liraglutide injection), Levemir® (insulin detemir), NovoMix® (biphasic insulin aspart), NovoRapid® (insulin aspart), and our pens & devices.
Novo Nordisk provides localized information to HCPs in the following countries:
Why only for Health Care Professionals
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Overview
Product information
Haemostasis
Educational
Disease areas
Why only for Health Care Professionals
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Overview
Pharmaceutical information
Indications
Injection devices
Needles
Programmes & support
Patient testimonials
Why only for Health Care Professionals
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Overview
Our products
About HRT
Why only for Health Care Professionals
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Careers
Working in
Programmes
Students & Graduates
Events
Facts about Novo Nordisk
The Novo Nordisk Way
Management
Publications & Presentations
Changing Diabetes®
Changing Possibilities in Haemophilia®
New domicile
Corporate Governance
Novo Nordisk Worldwide
About Novo Nordisk
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 35,500 employees in 75 countries, and markets its products in more than 180 countries.
Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
